Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendat...

Descripción completa

Detalles Bibliográficos
Autores principales: Homaira, Nusrat, Rawlinson, William, Snelling, Thomas L., Jaffe, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274815/
https://www.ncbi.nlm.nih.gov/pubmed/25548575
http://dx.doi.org/10.1155/2014/571609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274815/
https://www.ncbi.nlm.nih.gov/pubmed/25548575
http://dx.doi.org/10.1155/2014/571609

Ejemplares similares